Momcozy Showcases Latest Innovations at ABC Kids Expo 2025
Las Vegas, Nevada--(Newsfile Corp. - May 22, 2025) - Momcozy, a leading global brand in maternity and baby care, is proud to present its newest innovations at ABC Kids Expo 2025, taking place May 21-23 at Las Vegas. At Booth #110, Momcozy is showcasing a broad range of new products alongside fan favorites at this influential trade event.
Momcozy Showcases Latest Innovations at ABC Kids Expo 2025
First Offline Debut: Momcozy's Thinnest Wearable Breast Pump
Making its first in-person appearance since launching in March, the Momcozy Air 1 Ultra-Slim Breast Pump is the thinnest wearable breast pump on the market[1], measuring just 2.4 inches thick-nearly 22% thinner than Momcozy's Mobile Flow™. Its ultra-slim design and whisper-quiet motor combine to deliver an unprecedented level of discreet pumping experience.
Air 1 also features the industry's 1st transparent top-view design, allowing for easier alignment and milk volume monitoring. Its storage case doubles as a wireless charging station and, together with the pump, provides power for up to 15 sessions per charge.
"From Air 1, to Mobile Flow™ and Mobile Style™ , we continue to empower mothers to pump confidently anywhere through human-centered innovation," said Alan Cawley, senior sales director at Momcozy.
Introducing: The All-New Abdomen Solution
Momcozy also highlights its newly launched Ergowrap Postpartum Belly Band, complementing the brand's Ergonest Maternity Belly Band to offer a comprehensive abdomen solution for mothers. Engineered with the patented Ergonest Support Structure™, these bands help alleviate lower back pain, and provide comfortable support for daily activities, standing, and exercise.
Also on display is the CoolFit Nursing Bra Collection, released just last week. Designed for moms prone to overheating and sweating, the bras feature advanced Jelly Strip and seamless composite technology that adapt comfortably to changing breast shapes during pregnancy and breastfeeding.
A New Lineup of Smart Babycare Essentials
Momcozy introduces a variety of new babycare products, including:
Upgraded 2-in-1 Electric Nasal Aspirator: Equipped with powerful 65KPa hospital-grade suction and smart protection for effective nasal relief.
5-Inch Dual-Mode Smart Baby Monitor (BM04): Offers both Wi-Fi and non-Wi-Fi connectivity for flexible monitoring, safety alerts, and live sharing with up to 20 family members.
The brand is also showcasing popular products such as the ChangeGo Baby Stroller, a versatile stroller system that easily converts from a single to a double stroller, and even into a wagon. It supports 23 configurations with a variety of accessories, designed to grow with children from birth to age six.
Momcozy is rapidly expanding across retail, e-commerce, and medical channels worldwide. In the U.S., partnerships with Durable Medical Equipment (DME) providers allows eligible customers to access essentials like breast pumps through insurance, reinforcing the brand's commitment to innovation and accessibility.
Following the expo, all showcased products will be donated to Delivering Good, a nonprofit supporting at-risk children, families, and individuals. It's one more way Momcozy puts its values into action: making trusted maternity and baby care more accessible to families everywhere.
###
About Momcozy
Momcozy is a global mother and baby brand, serving over 3.6 million mothers in more than 60 countries and regions. Since 2018, we've evolved to meet the unique needs of moms and their families, offering a range of products from pregnancy through early motherhood, including wearable breast pumps, feeding gear, nursing bras, baby carriers, and more. As the Cozy Reformer, we always put moms first, delivering innovative solutions, comfort, and support to bring joy and ease to their journeys. Visit https://momcozy.com/ to learn more.
Media Contact: Phoebe xiaopr@momcozy.com
[1] Based on internal comparison of product thickness to the top 5 best-selling electric breast pumps on Amazon in the U.S., U.K., Germany, and France from Q1-Q3 2024.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253072
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 minutes ago
- Business Wire
Medincell: Half-Year Liquidity Contract Statement
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2025: 5 000 shares 1 145 177 € Over the period from 01/01/2025 to 30/06/2025, a total of : Number of executions Number of shares Traded volume in EUR Buy side 11,807 759,363 11,677,812.97 Sell side 11,343 758,413 11,671,875.50 Expand It should be noted that Medincell increased the funds allocated to the liquidity contract by €600,000 on 11 April 2025. At the time of its implementation on September 11, 2024, the following resources were included in the liquidity account: 8 824 shares 466 568.49 € About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are registered trademarks of Teva Pharmaceuticals. This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities. These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as "objective", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "should", "could" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements. A list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements. This press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions. Appendices – Rothschild Martin Maurel from 01/01/2025 to 30/06/2025 DATE NB_BUY NB_SALE QTE_BUY QTE_SALE CAPITAL_BUY CAPITAL_SALE 02/01/2025 89 132 1,607 5,257 26,949.39 89,631.85 03/01/2025 65 61 2,170 2,570 38,343.90 45,900.20 06/01/2025 111 85 3,509 2,609 63,758.53 47,562.07 07/01/2025 135 116 7,131 4,281 126,432.63 75,688.08 08/01/2025 63 66 3,356 3,356 57,924.56 58,025.24 09/01/2025 86 52 3,965 1,715 67,167.10 29,103.55 10/01/2025 70 43 2,336 1,336 39,011.20 22,391.36 13/01/2025 110 76 2,580 2,830 41,899.20 45,987.50 14/01/2025 50 51 1,848 1,848 30,196.32 30,362.64 15/01/2025 57 55 1,708 1,708 27,891.64 28,011.20 16/01/2025 31 51 2,238 3,238 36,277.98 52,585.12 17/01/2025 42 51 1,063 1,813 17,199.34 29,424.99 20/01/2025 47 32 1,971 1,971 32,028.75 32,068.17 21/01/2025 243 133 7,060 7,560 113,736.60 128,822.40 22/01/2025 48 75 1,456 2,706 23,179.52 43,323.06 23/01/2025 59 53 2,014 2,264 31,962.18 36,020.24 24/01/2025 44 98 1,850 2,810 29,507.50 45,044.30 27/01/2025 47 54 1,495 2,535 23,979.80 40,990.95 28/01/2025 61 135 555 1,555 9,301.80 25,828.55 29/01/2025 254 161 16,266 10,766 269,852.94 177,208.36 30/01/2025 226 230 16,770 16,520 259,767.30 256,060.00 31/01/2025 51 96 1,340 3,188 21,064.80 50,211.00 01/2025 1,989 1,906 84,288 84,436 1,387,432.98 1,390,250.83 03/02/2025 45 95 2,511 2,413 39,046.05 37,811.71 04/02/2025 48 47 2,065 2,065 32,895.45 32,978.05 05/02/2025 45 59 1,100 5,100 17,644.00 82,263.00 06/02/2025 41 39 1,826 1,826 29,928.14 29,946.40 07/02/2025 82 31 3,387 887 54,632.31 14,227.48 10/02/2025 161 69 4,812 2,062 74,537.88 32,167.20 11/02/2025 49 62 3,412 2,512 51,760.04 38,132.16 12/02/2025 52 38 1,643 1,793 24,743.58 27,038.44 13/02/2025 92 80 3,027 1,527 45,072.03 22,843.92 14/02/2025 156 160 4,414 3,414 63,164.34 48,547.08 17/02/2025 91 128 2,886 4,886 41,183.22 69,967.52 18/02/2025 144 95 3,940 3,403 55,238.80 47,744.09 19/02/2025 243 265 12,992 11,529 177,210.88 157,370.85 20/02/2025 245 126 3,818 4,318 52,039.34 59,070.24 21/02/2025 96 92 2,295 2,372 31,212.00 32,354.08 24/02/2025 78 54 1,618 1,541 22,020.98 21,065.47 25/02/2025 125 79 3,641 2,141 48,388.89 28,432.48 26/02/2025 240 295 6,989 11,489 95,819.19 160,156.66 27/02/2025 172 119 4,575 4,075 65,422.50 58,476.25 28/02/2025 110 109 2,625 2,625 37,170.00 37,511.25 02/2025 2,315 2,042 73,576 71,978 1,059,129.62 1,038,104.33 03/03/2025 80 110 832 2,532 11,964.16 36,435.48 04/03/2025 174 129 6,650 4,450 94,762.50 63,991.00 05/03/2025 117 266 8,281 11,081 119,163.59 159,677.21 06/03/2025 92 62 3,934 2,134 56,020.16 30,537.54 07/03/2025 122 153 8,000 7,000 112,320.00 98,280.00 10/03/2025 105 100 10,000 8,000 137,800.00 110,640.00 11/03/2025 84 77 3,416 2,156 46,491.76 29,450.96 12/03/2025 34 96 1,951 8,560 27,040.86 118,641.60 13/03/2025 106 94 7,706 5,757 107,421.64 80,425.29 14/03/2025 81 60 7,716 5,016 107,406.72 70,324.32 17/03/2025 71 114 7,879 10,921 109,518.10 152,020.32 18/03/2025 64 78 11,612 14,940 165,819.36 213,940.80 19/03/2025 91 112 11,437 11,808 166,865.83 172,396.80 20/03/2025 42 46 5,941 6,000 86,916.83 87,900.00 21/03/2025 71 87 9,902 9,152 147,935.88 137,005.44 24/03/2025 88 30 9,351 5,001 140,171.49 75,015.00 25/03/2025 67 56 4,661 3,961 69,029.41 58,662.41 26/03/2025 25 73 4,004 7,003 59,979.92 104,904.94 27/03/2025 67 45 6,457 4,558 96,467.58 68,005.36 28/03/2025 52 65 2,768 6,668 41,298.56 99,753.28 31/03/2025 91 30 7,061 1,361 102,808.16 20,006.70 03/2025 1,724 1,883 139,559 138,059 2,007,202.51 1,988,014.45 01/04/2025 106 93 8,067 6,567 115,922.79 94,433.46 02/04/2025 84 103 6,275 7,275 88,979.50 103,668.75 03/04/2025 55 27 4,332 3,422 61,124.52 48,318.64 04/04/2025 44 37 2,700 2,810 36,801.00 38,216.00 07/04/2025 2 3 150 570 1,923.00 7,341.60 08/04/2025 38 56 2,213 4,043 29,875.50 54,701.79 09/04/2025 63 50 4,913 3,463 64,311.17 45,053.63 10/04/2025 82 52 4,514 4,014 60,893.86 54,108.72 11/04/2025 74 50 4,515 3,690 58,559.55 47,970.00 14/04/2025 27 72 1,575 4,900 20,868.75 65,219.00 15/04/2025 31 57 1,525 4,025 21,106.00 55,625.50 16/04/2025 71 106 10,148 10,148 142,883.84 142,883.84 17/04/2025 54 66 4,844 4,844 68,300.40 68,494.16 22/04/2025 62 86 5,796 6,796 82,766.88 97,182.80 23/04/2025 121 110 10,326 10,326 150,966.12 151,172.64 24/04/2025 105 110 8,794 10,794 130,590.90 160,506.78 25/04/2025 115 58 9,039 4,039 136,217.73 60,544.61 28/04/2025 77 88 8,327 9,327 124,571.92 139,625.19 29/04/2025 96 107 10,750 10,750 160,927.50 161,250.00 30/04/2025 100 92 10,209 10,209 155,380.98 155,687.25 04/2025 1,407 1,423 119,012 122,012 1,712,971.91 1,752,004.36 02/05/2025 46 84 4,802 8,802 73,614.66 135,286.74 05/05/2025 102 103 10,750 9,500 164,045.00 145,350.00 06/05/2025 130 98 9,918 10,418 151,348.68 159,395.40 07/05/2025 110 92 7,131 7,881 109,104.30 120,894.54 08/05/2025 69 85 7,463 7,463 115,377.98 115,601.87 09/05/2025 48 36 4,721 4,721 73,553.18 73,600.39 12/05/2025 142 132 11,275 10,775 169,914.25 162,379.25 13/05/2025 113 92 11,500 10,000 174,455.00 151,700.00 14/05/2025 45 53 1,041 3,041 15,781.56 46,314.43 15/05/2025 69 13 5,050 1,050 77,063.00 15,960.00 16/05/2025 26 60 1,981 4,981 30,071.58 75,611.58 19/05/2025 52 44 3,166 4,166 49,421.26 65,072.92 20/05/2025 135 114 10,628 9,628 164,946.56 149,522.84 21/05/2025 50 80 3,791 4,791 59,025.87 74,979.15 22/05/2025 113 69 7,466 6,966 118,186.78 110,411.10 23/05/2025 145 141 5,722 5,722 91,609.22 92,410.30 26/05/2025 152 144 10,400 7,650 176,904.00 130,126.50 27/05/2025 85 125 8,270 10,020 140,259.20 170,039.40 28/05/2025 204 176 12,204 11,704 201,610.08 194,052.32 29/05/2025 145 123 12,000 9,357 199,680.00 155,887.62 30/05/2025 141 137 7,853 12,496 130,988.04 208,183.36 05/2025 2,122 2,001 157,132 161,132 2,486,960.20 2,552,779.71 02/06/2025 201 128 13,078 8,078 216,179.34 133,690.90 03/06/2025 193 156 10,185 10,657 164,589.60 173,282.82 04/06/2025 102 88 9,000 7,278 144,450.00 116,811.90 05/06/2025 89 139 5,250 11,500 84,892.50 186,415.00 06/06/2025 106 59 8,810 4,864 143,603.00 79,477.76 09/06/2025 83 76 6,319 6,223 101,040.81 99,692.46 10/06/2025 109 104 9,407 7,449 151,546.77 120,152.37 11/06/2025 134 73 10,000 4,000 158,300.00 63,360.00 12/06/2025 124 84 7,676 7,676 119,899.12 119,745.60 13/06/2025 158 128 9,356 9,356 144,363.08 144,456.64 16/06/2025 137 148 12,930 14,249 200,415.00 220,717.01 17/06/2025 99 53 11,926 3,624 181,871.50 55,048.56 18/06/2025 30 132 2,050 14,683 32,533.50 233,606.53 19/06/2025 64 103 5,849 9,699 95,748.13 159,548.55 20/06/2025 148 113 11,114 10,114 187,270.90 170,724.32 23/06/2025 101 84 12,940 9,440 223,991.40 163,123.20 24/06/2025 91 71 8,216 5,353 138,193.12 91,803.95 25/06/2025 58 123 4,825 8,688 81,397.75 147,087.84 26/06/2025 71 48 7,843 6,302 132,076.12 106,629.84 27/06/2025 67 106 9,209 12,750 155,816.28 216,495.00 30/06/2025 85 72 9,813 8,813 165,937.83 148,851.57 06/2025 2,250 2,088 185,796 180,796 3,024,115.75 2,950,721.82 S1/2025 11,807 11,343 759,363 758,413 11,677,812.97 11,671,875.50 Expand
Business Wire
10 minutes ago
- Business Wire
PGT Introduces New Panel Sizes for Popular Preferred View Sliding Glass Door
VENICE, Fla.--(BUSINESS WIRE)--PGT Custom Windows and Doors, part of the MITER Brands portfolio and America's authority in high-performance windows and doors, announced today the launch of larger panel sizes for its WinGuard ® Aluminum Preferred View Sliding Glass Door (SGD770NS). "True to its name, the Preferred View Sliding Glass Door delivers wide-open views and natural light like never before,' said Brian Covey, Vice President of Sales, MITER Brands-South. The Preferred View Sliding Glass Door now offers door panels with up to 60 square feet of glass in sizes as large as 6' wide x 10' tall or 5' wide x 12' tall. These expanded dimensions are available in a variety of operating configurations depending on panel height. All sizes up to 12' tall are offered in bypass and pocket configurations, while 90-degree or 135-degree corner configurations are available for doors with panels up to 10' in height. 'Over the past decade, we've seen consistent demand for more glass and less frame,' said Brian Covey, Vice President of Sales, MITER Brands-South. 'This latest enhancement gives homeowners the expansive sizes and minimal sightlines they're looking for. True to its name, the Preferred View Sliding Glass Door delivers wide-open views and natural light like never before.' Since its launch in 2023, the Preferred View Sliding Glass Door has become a favorite among homeowners and builders for its narrow 2.5' interlocks—half the width of standard designs—and its ability to scale up to 8 panels wide. Now capable of creating openings up to 48 feet wide, the door offers a striking way to maximize views, integrate indoor and outdoor spaces seamlessly, and develop a sense of openness in any room. Part of PGT's WinGuard Aluminum impact-resistant door series, the Preferred View Sliding Glass Door features a robust aluminum frame engineered for durability, long-lasting strength, and performance. The door is also equipped with heavy-duty tandem rollers for smooth, fingertip opening. At the same time, a dual-point locking mechanism enhances security by preventing the panels from being lifted off the tracks. With the addition of larger panel sizes for the Preferred View Sliding Glass Door, PGT continues to push the boundaries of innovation and design, offering homeowners bold new ways to customize their living spaces with the sleek and modern aesthetics they desire. Learn more about PGT at ABOUT PGT CUSTOM WINDOWS AND DOORS PGT Custom Windows and Doors, part of the MITER Brands portfolio, is America's authority in high-performance windows and doors. With decades of proven industry leadership and over 8+ million units installed, PGT Custom Windows and Doors has a consistent track record of leading the space with an unwavering focus on safety and innovation. Its product lines include WinGuard ® aluminum and vinyl frames for impact resistant windows, ClassicVue Max™ aluminum frames for non-impact windows, and EnergyVue ® vinyl frames for non-impact windows. PGT Custom Windows and Doors has a primary focus of protecting families' lifestyle choices with a commitment of delivering industry-best service. Backed by innovative technology, homeowners can enjoy their home life with greater peace of mind, wherever they choose to live, knowing they are protected from storms, noise, and intrusion. For more information, visit About MITER Brands Founded in 1947, MITER Brands is a residential window and door manufacturer that produces a portfolio of window and door brands for the new construction and replacement segments with an owner-operated, family-first approach. With more than 20 manufacturing facilities throughout the United States, MITER Brands is a nationwide supplier of precision-built and energy-efficient products. Through optimized manufacturing, valued relationships, and dedicated team members coast to coast, MITER Brands instills confidence and drives quality customer experiences. The name 'MITER' is an acronym reflecting five of our core strengths: Manufacturing, Innovation, Trust, Experiences, and Relationships. For more information, visit
Business Wire
40 minutes ago
- Business Wire
Molecular Instruments® Continues RNA Imaging Leadership with Next-Generation miRNA/siRNA Detection and Clinical-Grade Ready-to-Use Kits
LOS ANGELES--(BUSINESS WIRE)--Molecular Instruments® (MI), the inventor of the HCR™ platform, today announced key enhancements to its HCR™ Gold and HCR™ Pro product lines. These upgrades include next-generation chemistry for high-specificity detection of small RNA targets—including microRNAs (miRNAs) and small interfering RNAs (siRNAs)—and the introduction of a new ready-to-use, prefilled dispenser format for automated assay workflows. 'With small RNA detection and ready-to-use dispensers, HCR™ Pro and HCR™ Gold are setting a new standard for clinical-grade workflows." Share Together, these advances represent a pivotal development in delivering clinical-grade RNA imaging performance with seamless, high-throughput usability. Next-Generation HiFi Chemistry Unlocks Small RNA Detection Both HCR™ Gold and HCR™ Pro now incorporate next-generation HCR™ HiFi architecture, enabling robust detection of small RNAs such as miRNA and siRNA with built-in automatic background suppression, allowing for unmatched signal-to-background performance. Researchers can now visualize and quantify low-abundance, short-length targets with the same confidence as typical transcripts—driving new biological insights across both foundational research and translational discovery. Prefilled Dispensers Support Scalable, Clinical-Grade Performance Additionally, MI has begun shipping HCR™ Pro kits in a fully prefilled dispenser format for the DISCOVERY ULTRA automated research platform. This ready-to-use packaging eliminates manual reagent preparation, streamlining setup and minimizing variability between users and runs. By simplifying the workflow and enhancing reproducibility, these prefilled kits mark a critical milestone on the path toward scalable, clinical-grade molecular imaging. 'These upgrades are a major step forward in our vision to make high-performance bioimaging effortless and with the highest levels of precision,' said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. 'With small RNA detection and ready-to-use dispensers, HCR™ Pro and HCR™ Gold are setting a new standard for clinical-grade workflows.' The prefilled format is now available for an initial automation platform, with broader compatibility in development. To learn more or place an order, visit About Molecular Instruments Molecular Instruments® ( is a company powering the future of bioimaging through the development of clinical-grade molecular detection technologies. The company offers automated and manual chromogenic and fluorescent in situ hybridization (ISH) assays that seamlessly integrate with existing immunohistochemistry (IHC) and immunofluorescence (IF) workflows. With thousands of users globally, MI is establishing the field standard for RNA detection and supporting applications from academic research to drug development and diagnostics.
